Metabolic

Cagrilintide

Metabolic Compound

Also referred to as AM833.

Cagrilintide is a long-acting, lipidated analogue of amylin, a pancreatic hormone co-secreted with insulin that signals satiety. Natural amylin has a short half-life and tendency to form amyloid fibrils; Novo Nordisk engineered a stabilised, fatty-acid-conjugated molecule capable of once-weekly subcutaneous administration for chronic weight management research.

The compound has accumulated substantial human trial data, including a 26-week phase 2 monotherapy trial and phase 3a combination studies with semaglutide (CagriSema). Independent monotherapy evidence remains limited to the single phase 2 trial, and long-term cardiovascular outcome data has not yet been published.

Published on Cagrilintide

Research OverviewCagrilintide Peptide: Safety, Side Effects, and Risks in the ResearchCagrilintide is a long-acting, lipidated amylin analogue developed as a once-weekly subcutaneous injection for weight management.
Research OverviewCagrilintide Peptide Before and After: What Published Research DocumentsCagrilintide is a long-acting, lipidated amylin analogue engineered to replicate and extend the satiety-signaling actions of amylin, a pancreatic hormone co-secreted with insulin at mealtimes.
Research OverviewCagrilintide Peptide: Mechanism of Action ExplainedCagrilintide is a long-acting, lipidated analogue of amylin, a pancreatic hormone co-secreted with insulin from beta cells in response to meals.